Investigational — not approved anywhere
Ulotaront
What it isUlotaront is an investigational trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity that lacks direct dopamine D2 receptor blockade.
Why this oneIt was developed as a non-D2 antipsychotic for schizophrenia intended to avoid extrapyramidal and metabolic adverse effects.
What limits itIt failed to separate from placebo in the Phase 3 DIAMOND 1 and DIAMOND 2 trials and is not FDA approved.
NO BOXED WARNINGS
Principal riskNo FDA boxed warning (investigational).
Classes and tags
Clinical profile
Mechanism of action: Ulotaront ballicule
Open Ulotaront in the interactive console ↗
Memory aids: mascots and interaction avatars
